

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTAU188MXM

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/Caplus -Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 OCT 03 MATHDI removed from STN
NEWS 9 OCT 04 CA/Caplus-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 10 OCT 06 STN AnaVist workshops to be held in North America
NEWS 11 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 12 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of Caplus documents for use in third-party analysis and
visualization tools

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:57:38 ON 17 OCT 2005

=> file ca, biosis, medline

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'CA' ENTERED AT 18:57:47 ON 17 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 18:57:47 ON 17 OCT 2005

Copyright (c) 2005 The Thomson Corporation

=> s (betaine hcl) or (betaine hdrochloric acid)
 L1 242 (BETAINE HCL) OR (BETAINE HROCHLORIC ACID)

=> s (betaine hcl) or (betaine hydrochloric acid)
 L2 242 (BETAINE HCL) OR (BETAINE HYDROCHLORIC ACID)

=> s pepsin
 L3 41098 PEPSIN

=> s 12 and 13
 L4 13 L2 AND L3

=> d 1-13 ab,bib

L4 ANSWER 1 OF 13 CA COPYRIGHT 2005 ACS on STN

AB The present invention provides a stabilized protonic formulation comprised primarily of proteins, enzymes and pH adjusters, all in specific ratios to one another, a liquid medium which, when combined to the protonic formulation, initiates activation of the amino acids within the protonic formulation, and a stabilizing component which stabilizes the amino acids during the process of their activation. The optimum ratio of enzyme activator formulation to protein mixture is about 1:25, though 1 part enzyme activator formulation to 10 to 30 parts protein mixture will function suitably for the intended purpose. The enzyme activator formulation is optimally comprised of: **betaine-HCl** 4.0%, **pepsin** 1.5%, trypsin 0.4%, chymotrypsin 0.3%, protease 0.4%, bromelain 0.5%, papaya 0.6%, vitamin C 5.0%, lemon powder 0.6%, glutamic acid 0.2%, and glycine 86.4%. The protein sources and mixture that works best with the enzyme activator formulation includes: whey protein isolate 30.0%, instant whey concentrate 15.0%, soy protein isolate 25.0%, pea protein 5.0%, rice protein 5.0%, maltodextrin 15.7%, steviocide 0.3%, french vanilla flavor 1.75%, peach mango flavor 0.5%, xanthan gum 0.5%, lecithin 0.5%, and tricalcium phosphate 0.75%. Clin. tests and studies have shown that, with use of the protonic mixture, about 30 to 40% more amino acids are utilized than when the protonic mixture is not used.

AN 143:114482 CA

TI Protein formulation comprising enzymes and pH adjusters for improved bioavailability of amino acids

IN Ernest, Michael

PA Doctor's Signature Sales and Marketing International Corp., USA

SO U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005152887	A1	20050714	US 2004-757706	20040114
PRAI	US 2004-757706		20040114		

L4 ANSWER 2 OF 13 CA COPYRIGHT 2005 ACS on STN

AB A complex enzyme composition that improves growth and feed digestion by animals comprises pancreatin 200, **betaine-HCl** 50, monobasic calcium phosphate 100, α -amylase 150, β -amylase 100, lipase 50, **pepsin** 100, and cellulase 100 mg.

AN 142:218044 CA

TI Complex enzyme composition containing pancreatin, **betaine-HCl**, and calcium phosphate as feed additive

IN Han, In Kyu

PA S. Korea

SO Repub. Korean Kongkae Taeho Kongbo, No pp. given

CODEN: KRXXA7

DT Patent

LA Korean

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	KR 2002041162	A	20020601	KR 2000-70943	20001127
PRAI	KR 2000-70943		20001127		

L4 ANSWER 3 OF 13 CA COPYRIGHT 2005 ACS on STN

AB A composition containing betaine hydrochloride and **pepsin** as powders, pancreatin, α -amylase, β -amylase, lipase, cellulase, dibasic calcium phosphate as an enzyme complex, Lactobacillus acidophilus, Bifidobacteria longum, fructooligosaccharide or the like as a probiotics complex, a vitamin complex and a mineral complex is provided which inhibits proliferation of intestinal harmful microorganisms and enhances immunoactivity. The composition contains 78 mg **betaine HCl**, 50 mg **pepsin**, 15 mg pancreatin, 11 mg α -amylase, 8 mg β -amylase, 4 mg lipase, 7.5 mg cellulase, 7.5 mg dibasic calcium phosphate, 1.25 billion Lactobacillus acidophilus, Lactobacillus bulgaricus, etc. 900 million Bifidobacteria longum and Bifidobacterium breve, 180 million Streptococcus thermophilus, 375 mg fructooligosaccharide, 450 IU vitamin A, 675 IU β -carotene, 56 mg vitamin C, 23 IU vitamin D, 23 IU vitamin E, 7.5 μ g vitamin K, 3.8 mg thiamine, 3.4 mg riboflavin, 5.6 mg niacin, 3.4 mg pyridoxine, 11 μ g cobalamin, 28 μ g biotin, 8.4 mg pantothenic acid, 8.4 mg choline, 28.1 mg Ca, 18.8 mg P, 0.9 mg Fe, 12 μ g I, 17 mg Mg, 1.7 mg Zn, 11 μ g Se, 0.1 mg sulfuric acid, 0.6 mg Mn, 11 μ g chromium picolinate, 0.6 mg Mo, 0.6 mg K, 0.3 mg betaine, 0.2 mg B, 3.8 mg L-lysine 2.0 mg phenylalanine, 2.0 mg L-tyrosine, a trace amount of kelp powder and 4.7 mg polyunsatd. fatty acid.

AN 142:204717 CA

TI Nutrients containing betaine, enzymes, Lactobacillus, Bifidobacteria, fructooligosaccharides, vitamins and minerals

IN Han, In Kyu; Kim, Yu Yong

PA S. Korea

SO Repub. Korean Kongkae Taeho Kongbo, No pp. given
CODEN: KRXXA7

DT Patent

LA Korean

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	KR 2003025587	A	20030329	KR 2001-58713	20010921
PRAI	KR 2001-58713		20010921		

L4 ANSWER 4 OF 13 CA COPYRIGHT 2005 ACS on STN

AB A protonic formulation is provided comprising a protein mixture and a mix. of enzymes and pH adjusters selected for proper activation, pH adjustment, and attainment of pK for the amino acids and optimization of bioavailability of the amino acids. The optimum ratio of enzyme activator formulation to protein mixture is about 1:25, though 1 part enzyme activator formulation to 10-30 parts protein mixture will function suitably for the intended purpose. The enzyme activator formulation is optimally comprised of: **betaine-HCl** 4.0%, **pepsin** 1.5%, trypsin 0.4%, chymotrypsin 0.3%, protease 0.4%, bromelain 0.5%, papaya 0.6%, vitamin C 5.0%, lemon powder 0.6%, glutamic acid 0.2%, and glycine 86.4%. The protein sources and mixture that works best with the enzyme activator formulation includes: whey protein isolate 30.0%, instant whey concentrate 15.0%, soy protein isolate 25.0%, pea protein 5.0%, rice protein 5.0%, maltodextrin 15.7%, steviolide 0.3%, french vanilla flavor 1.75%, peach mango flavor 0.5%, xanthan gum 0.5%, lecithin 0.5%, and tricalcium phosphate 0.75%. Clin. tests have shown that, with use of the protonic mixture, about 30-40% more amino acids are utilized than when the protonic mixture is not used.

AN 138:169167 CA

TI Protein formulation with enzymes and pH adjusters for improved bioavailability of amino acids

IN Ernest, Michael

PA Life Force International, USA

SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003014304	A2	20030220	WO 2002-US24662	20020802
	WO 2003014304	A3	20030501		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-311280P	P	20010809		

L4 ANSWER 5 OF 13 CA COPYRIGHT 2005 ACS on STN
AB An herbal formulation useful as a food supplement for re-establishing intestinal bacteria and rebuilding intestinal mucosa comprises 25-35% **betaine HCl**, 2-7% plant enzymes, 1-4% papain, 0.5-5% probiotic micro flora, 2-7% fructooligosaccharides, 5-15% L-glutamine, 2-7% quercitin, 2-7% butyric acid, 5-15% borage seed, 5-15% flax seed, 5-10% lecithin, and 5-15% of a mixture containing γ -oryzanol, bromelain, **pepsin**, and N-acetylglucosamine. The formulation may be mixed together, compressed and formed into a capsule for oral administration.
AN 137:129879 CA
TI Herbal formulation containing enzymes for rebuilding intestinal bacteria
IN Terry, Travis L.; Watson, Tommy Stanley; Watson, Brenda F.
PA Renew Life, Inc., USA
SO U.S., 3 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6426099	B1	20020730	US 1998-204036	19981201
PRAI	US 1997-67271P	P	19971203		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 13 CA COPYRIGHT 2005 ACS on STN
AB The therapeutic efficacy of dexamethasone and a natural pig surfactant preparation was investigated in a rabbit aspiration model. Lung injury was induced by intratracheal administration of 2 mL of a **betaine-HCl-pepsin** mixture/kg. Dexamethasone was given i.v. in two doses (D1 = 7.5 mg/kg; D2 = 3.75 mg/kg; D2 6 h post D1). In different groups D1 was injected at different times before and after aspiration. Natural surfactant was administered 24 h post lung injury in a single dose of 12 mg phospholipids/kg. The therapeutic potential was evaluated by measuring static lung compliance and the difference in a lung volume between 0 and 20 mm Hg airway pressure. No therapeutic effect of dexamethasone was seen at any time of application. In contrast, the intratracheal administration of natural surfactant 24 h post injury completely reversed the deterioration of lung mech. properties.
AN 119:86523 CA
TI Experimental aspiration trauma: Comparison of steroid treatment versus exogenous natural surfactant
AU Strohmaier, W.; Schlag, G.
CS Ludwig Boltzmann Inst. Exp. Clin. Traumatol., Vienna, Austria
SO Experimental Lung Research (1993), 19(3), 397-405
CODEN: EXLRDA; ISSN: 0190-2148
DT Journal
LA English

L4 ANSWER 7 OF 13 CA COPYRIGHT 2005 ACS on STN
AB Pharmaceuticals for treatment of digestive tract disorders in domestic animals contain **betaine-HCl** 10-30, antacid carbohydrate digestive enzymes 1-10, antacid cellulose-degrading enzymes 1-10, antacid protein digestive enzymes 20-40, and saccharification bacteria spore powder 10-30% by weight. Thus, a pharmaceutical was prepared by mixing **betaine-HCl** 200, carbohydrate digestive enzyme 50, a cellulose degrading enzyme 50, sugar-containing **pepsin** 300, saccharification bacterial spore powder 200, lactose 100 parts by weight, and potato starch q.s.

AN 112:62655 CA

TI Pharmaceuticals for treatment of digestive tract disorders of domestic animals

IN Masuda, Takashi

PA Toa Yakuhin Kogyo K. K., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01132533	A2	19890525	JP 1987-289628	19871118
PRAI	JP 1987-289628		19871118		

L4 ANSWER 8 OF 13 CA COPYRIGHT 2005 ACS on STN

AB The characteristic enzymic activity, using the gastrointestinal model, of the acid-resistant digestive enzyme which had been added to the preparation containing **betaine-HCl** was determined and compared with those of folk digestive enzyme prepsns. The deviation of the wts. of those prepsns. was also investigated. The present preparation shows it digestive activity in the acid range and act in the stomach. The digestive activity using the shaking methods and the separated methods, i.e. amylase, protease and lipase did not fulfill the standard activity of the digestive enzyme prepsns. The digestion using the gastrointestinal model was about the same as that of the digestive enzyme prepsns. fulfilling th criteria and, especially in the gastric model, it was same or more than that. The prepsns. in which more than 2 types of granules, had been mixed fulfilled the requirements of the weight variation in the Japanese Pharmacopoeis, but the mixture ratio of those was variable.

AN 109:176308 CA

TI The characteristic digestive activity of the preparation containing betaine hydrochloride

AU Murakami, Tadayasu; Kawashima, Mikio; Sasaki, Masanori; Kobayashi, Shinichi; Yamada, Fusayo; Asahina, Kikuo

CS Res. Lab., Toa Pharm. Co., Ltd., Tatebayashi, 374, Japan

SO Yakuri to Chiryo (1973-2000) (1988), 16(2), 771-8

CODEN: YACHDS; ISSN: 0386-3603

DT Journal

LA Japanese

L4 ANSWER 9 OF 13 CA COPYRIGHT 2005 ACS on STN

AB Oval compns. for decreasing the symptoms of digestive dysfunction contain a pancreatic enzyme extract, a protelytic enzyme from plants, a choleretic agent, a HCl source and **pepsin** [9001-75-6]. Bromelain [9001-00-7] and pancreatin [8049-47-6] were adsorbed onto digestible sucrose-starch beads which were coated with while lac glaze. These beads were then coated with stearic acid and carnauba wax. A mixture of ox bile extract, **pepsin**, **betaine-HCl** [590-46-5] and guar gum was blended with H2O to give a dough which was screened, dried, and the resultant granules ground and dry-screened to the mesh. The granules were mixed with the coated beads and blended with hydrogenated vegetable oil, microcryst. cellulose, and Mg stearate. The mixture was punched into tablets and coated with a zein solution

AN 101:28325 CA

TI Enzyme-containing digestive aid compositions

IN Bilton, Gerald L.

PA USA

SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4447412	A	19840508	US 1983-462995	19830201
	WO 8503438	A1	19850815	WO 1984-US159	19840203
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, LU, NL, SE				
	EP 172166	A1	19860226	EP 1984-901130	19840203
	R: AT, BE, CH, DE, FR, GB, LI, LU, NL, SE				
	CA 1213543	A1	19861104	CA 1984-447208	19840210
PRAI	US 1983-462995		19830201		
	WO 1984-US159	A	19840203		

L4 ANSWER 10 OF 13 CA COPYRIGHT 2005 ACS on STN
AB A review with refs. of **betaine-HCl** [590-46-5], glutamic acid-HCl [138-15-8], diluted HCl, and **pepsin** [9001-75-6] as ingredients in over-the-counter (OTC) drug products for use as stomach acidifiers. Based upon the lack of adequate data to establish the effectiveness of these or any other ingredients of stomach acidifiers used in treating achlorhydria and hypochlorhydria, and because such conditions are asymptomatic and not amenable to self-diagnosis, any OTC drug product containing ingredients offered for use as stomach acidifiers cannot be considered generally recognized as safe and effective.

AN 92:47160 CA
TI Stomach acidifier drug products for over-the-counter human use; proposed rulemaking
CS Food and Drug Administration, Rockville, MD, 20857, USA
SO Federal Register (1979), 44(204), 60316-20, 19 Oct 1979
CODEN: FEREC; ISSN: 0097-6326
DT Journal; General Review
LA English

L4 ANSWER 11 OF 13 CA COPYRIGHT 2005 ACS on STN
AB A combination of 455 mg. **betaine-HCl** and 60 mg. **pepsin** (1:10,000 U.S.P. unit), having the mixed powder particles coated with 141 mg. methylcellulose, is placed in capsules. The mixture is useful as a gradual producer of HCl in patients with achlorhydria or hypochlorhydria. Glutamic acid-HCl can replace the **betaine-HCl**.

AN 51:83316 CA
OREF 51:15073b-c
TI Preparation containing betaine hydrochloride for treatment of achlorhydria and hypochlorhydria
IN Sahyun, Melville
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2798837		19570709	US	

L4 ANSWER 12 OF 13 CA COPYRIGHT 2005 ACS on STN
AB Betaine unites with HCl loosely to form a compound which readily breaks up into its components in aqueous solution. Because of this property the substance forms a convenient medium for the administration of HCl. **Betaine-HCl** contains 23.8% of HCl. Acidol is a proprietary name for the substance and its mixts. with **pepsin** are called "acidol-**pepsin**." **Betaine-HCl** is a white, crystalline, odorless substance of an acid reaction and taste. About 10 yrs. ago the acid contents of acidol and of acidol-**pepsin** were determined. The amts. found were substantially as claimed. The acid was determined by titration with N KOH, using phenolphthalein as indicator, and by precipitation with AgNO₃ and weighing as AgCl. Recently new specimens of each product were examined. The old products were reexamd. and the results compared. The acidity and

the proteolytic activity of the new specimens were essentially as claimed. The acidity of the old specimens had not changed much in 10 yrs., but the proteolytic activity had disappeared.

AN 14:18796 CA

OREF 14:3501b-d

TI Acidol and acidol-**pepsin**

AU Anon.

SO Rep. Lab. Am. Med. Assoc. (1919), 12, 91-3

DT Journal

LA Unavailable

L4 ANSWER 13 OF 13 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AB An herbal formulation comprises **betaine HCl**, plant enzymes, papain, probiotic micro flora, fruitooligosaccharides, l-glutamine, quercitin, butyric acid, borage seed, flax seed, lecithin, gamma oryzanol, bromelain, **pepsin**, and N-acetylglucosamine.

AN 2002:477375 BIOSIS

DN PREV200200477375

TI Herbal formulation for rebuilding intestinal bacteria.

AU Terry, Travis L. [Inventor, Reprint author]; Watson, Tommy Stanley [Inventor]; Watson, Brenda F. [Inventor]

CS Clearwater, FL, USA

ASSIGNEE: Renew Life, Inc., Clearwater, FL, USA

PI US 6426099 20020730

SO Official Gazette of the United States Patent and Trademark Office Patents, (July 30, 2002) Vol. 1260, No. 5. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

CODEN: OGUPE7. ISSN: 0098-1133.

DT Patent

LA English

ED Entered STN: 11 Sep 2002

Last Updated on STN: 11 Sep 2002